As a growing number of companies jostle for position in the emerging market for gene-synthesis services, some are turning to software as a way to differentiate themselves from their competitors.
This week, MWG Biotech of Ebersberg, Germany, announced that it has developed a new software program for “optimizing” synthetic genes. The software, called GENEius and developed in collaboration with partner Eurofins Medigenomix, is primarily for internal use as part of MWG’s gene-synthesis service.